Nicholas Investment Partners LP Has $1 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Nicholas Investment Partners LP reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 99.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,072 shares of the medical device company's stock after selling 2,741,928 shares during the period. Nicholas Investment Partners LP's holdings in DexCom were worth $1,002,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in DXCM. Valley National Advisers Inc. lifted its holdings in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. MV Capital Management Inc. lifted its holdings in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Smithfield Trust Co lifted its holdings in DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company's stock valued at $40,000 after acquiring an additional 165 shares during the last quarter. Washington Trust Advisors Inc. lifted its holdings in DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company's stock valued at $44,000 after acquiring an additional 193 shares during the last quarter. Finally, NBC Securities Inc. acquired a new position in DexCom in the third quarter valued at approximately $47,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DXCM has been the subject of several research analyst reports. Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They set an "outperform" rating and a $165.00 price target for the company. Citigroup raised their price target on DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a research report on Wednesday, April 3rd. Canaccord Genuity Group raised their price target on DexCom from $144.00 to $145.00 and gave the stock a "buy" rating in a research report on Friday, April 26th. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a research note on Wednesday, April 10th. Finally, StockNews.com cut DexCom from a "buy" rating to a "hold" rating in a research note on Thursday, May 9th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $141.67.

DexCom Stock Performance

Shares of NASDAQ DXCM traded up $1.02 during midday trading on Tuesday, reaching $125.97. 2,202,568 shares of the company were exchanged, compared to its average volume of 2,938,563. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The stock has a fifty day simple moving average of $133.36 and a 200 day simple moving average of $122.31. The stock has a market cap of $50.10 billion, a P/E ratio of 81.27, a PEG ratio of 2.17 and a beta of 1.23.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. On average, research analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the business's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Kevin R. Sayer sold 81,007 shares of the company's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now directly owns 333,526 shares of the company's stock, valued at approximately $44,479,027.36. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 14,639 shares of the company's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the sale, the chief operating officer now directly owns 273,913 shares of the company's stock, valued at $36,816,646.33. The disclosure for this sale can be found here. Insiders sold 190,004 shares of company stock worth $25,610,270 in the last ninety days. Insiders own 0.30% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.